menu
    • menu
    [{"orgOrder":0,"company":"Medlab Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Medlab Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Medlab Clinical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medlab Clinical \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||estrogens","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||estrogens","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Grunenthal","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||estrogens","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Grunenthal","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Grunenthal"},{"orgOrder":0,"company":"Mesoblast","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||estrogens","graph1":"Neurology","graph2":"Phase III","graph3":"Mesoblast","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mesoblast \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mesoblast \/ Undisclosed"},{"orgOrder":0,"company":"Medical Developments International","sponsor":"PERUKI | Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Methoxyflurane","moa":"GABA-A receptor; anion channel | Glycine receptor (alpha-1\/beta)","graph1":"Neurology","graph2":"Phase III","graph3":"Medical Developments International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Medical Developments International \/ PERUKI | Quintiles Inc","highestDevelopmentStatusID":"10","companyTruncated":"Medical Developments International \/ PERUKI | Quintiles Inc"},{"orgOrder":0,"company":"Medical Developments International","sponsor":"ORION Clinical Services","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Methoxyflurane","moa":"GABA-A receptor; anion channel | Glycine receptor (alpha-1\/beta)","graph1":"Neurology","graph2":"Phase III","graph3":"Medical Developments International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Developments International \/ ORION Clinical Services","highestDevelopmentStatusID":"10","companyTruncated":"Medical Developments International \/ ORION Clinical Services"},{"orgOrder":0,"company":"Invex Therapeutics","sponsor":"Premier Research Group | University Hospital Birmingham | University of Iowa","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Exenatide","moa":"Glucagon-like peptide 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Invex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Invex Therapeutics \/ Premier Research Group | University Hospital Birmingham | University of Iowa","highestDevelopmentStatusID":"10","companyTruncated":"Invex Therapeutics \/ Premier Research Group | University Hospital Birmingham | University of Iowa"},{"orgOrder":0,"company":"RDC Clinical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Palmitoylethanolamide","moa":"TNF-alpha receptor","graph1":"Neurology","graph2":"Phase III","graph3":"RDC Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RDC Clinical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"RDC Clinical \/ Undisclosed"},{"orgOrder":0,"company":"Medlab Clinical","sponsor":"George Clinical | WriteSource Medical Pty Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Delta 9 Tetrahydrocannabinol","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Medlab Clinical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Medlab Clinical \/ George Clinical | WriteSource Medical Pty Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Medlab Clinical \/ George Clinical | WriteSource Medical Pty Ltd"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mesoblast

                            Australia arrow
                            Aquaexpo
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rexlemestrocel-L,Hyaluronic Acid

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enrollment Commences in Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

                            Details : Revascor (rexlemestrocel-L) is preparation of immunoselected and culture-expanded mesenchymal precursor cells. It is being evaluated for the treatment of moderate to severe chronic low back pain.

                            Product Name : Revascor

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 21, 2024

                            Lead Product(s) : Rexlemestrocel-L,Hyaluronic Acid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medlab Clinical

                            Australia arrow
                            Aquaexpo
                            Not Confirmed

                            Medlab Clinical

                            Australia arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medlab Announces Favourable Interim Readout of Nanabis Real-World Evidence (RWE) Medcare Study

                            Details : NanaBis™ (tetrahydrocannabinol) is an investigative novel analgesic for cancer patients comprising equal parts of CBD and THC encapsulated in Medlab’s patented delivery platform, NanoCelle®. NanaBis™ is applied to the oro-buccal membrane for rapid...

                            Product Name : NanaBis

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 12, 2023

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Invex Therapeutics

                            Australia arrow
                            Aquaexpo
                            Not Confirmed

                            Invex Therapeutics

                            Australia arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exenatide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Premier Research Group | University Hospital Birmingham | University of Iowa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial to Determine the Efficacy and Safety of Presendin in IIH

                            Details : Presendin (Exenatide) is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pseudotumor Cerebri.

                            Product Name : Presendin

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            April 26, 2022

                            Lead Product(s) : Exenatide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Premier Research Group | University Hospital Birmingham | University of Iowa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mesoblast

                            Australia arrow
                            Aquaexpo
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rexlemestrocel-L,Hyaluronic Acid

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose of Mesoblast’s Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years ...

                            Details : Phase 3 trial of its allogeneic cell therapy MPC-06-ID ( rexlemestrocel-L), showed a durable reduction in back pain lasting at least three years from a single intra-discal injection in patients with chronic low back pain (CLBP) associated with degenerati...

                            Product Name : Revascor

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            January 11, 2022

                            Lead Product(s) : Rexlemestrocel-L,Hyaluronic Acid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Mesoblast

                            Australia arrow
                            Aquaexpo
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rexlemestrocel-L,Hyaluronic Acid

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Grunenthal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA’s OTAT in Agreement With 12-Month Reduction in Pain as Primary Endpoint for Chronic Low Back Pain Progra...

                            Details : A key objective of MPC-06-ID (rexlemestrocel-L) is to demonstrate reduction in pain and opioid usage and and position rexlemestrocel-L as a potential opioid-sparing agent.

                            Product Name : Revascor

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 15, 2021

                            Lead Product(s) : Rexlemestrocel-L,Hyaluronic Acid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Grunenthal

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            RDC Clinical

                            Australia arrow
                            Aquaexpo
                            Not Confirmed

                            RDC Clinical

                            Australia arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palmitoylethanolamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating the Effectiveness of PEA Compared to Placebo for Reducing Pain Severity and Duration of Mig...

                            Details : Palmitoylethanolamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 16, 2021

                            Lead Product(s) : Palmitoylethanolamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Medlab Clinical

                            Australia arrow
                            Aquaexpo
                            Not Confirmed

                            Medlab Clinical

                            Australia arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Delta 9 Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : George Clinical | WriteSource Medical Pty Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NanaBisâ„¢ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine fo...

                            Details : Delta 9 Tetrahydrocannabinol is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cancer Pain.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 22, 2021

                            Lead Product(s) : Delta 9 Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : George Clinical | WriteSource Medical Pty Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Mesoblast

                            Australia arrow
                            Aquaexpo
                            Not Confirmed

                            Mesoblast

                            Australia arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rexlemestrocel-L,Hyaluronic Acid

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Injection of Mesoblasts' Rexlemestrocel-L + Hyaluronic Acid Carrier Lowers Pain for at Least 2 Years in...

                            Details : A single injection of rexlemestrocel-L may provide a durable, and effective opioid-sparing therapy for patients with chronic inflammatory back pain due to degenerative disc disease. Greatest benefits were seen when administered earlier in the disease pro...

                            Product Name : Revascor

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 10, 2021

                            Lead Product(s) : Rexlemestrocel-L,Hyaluronic Acid

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Medical Developments International

                            Australia arrow
                            Aquaexpo
                            Not Confirmed

                            Medical Developments International

                            Australia arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methoxyflurane

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : PERUKI | Quintiles Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Methoxyflurane Analgesia for Paediatric Injuries

                            Details : Methoxyflurane is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2017

                            Lead Product(s) : Methoxyflurane

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : PERUKI | Quintiles Inc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Medical Developments International

                            Australia arrow
                            Aquaexpo
                            Not Confirmed

                            Medical Developments International

                            Australia arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methoxyflurane

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : ORION Clinical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma

                            Details : Methoxyflurane is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 19, 2011

                            Lead Product(s) : Methoxyflurane

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : ORION Clinical Services

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth